Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 1347 entries
Sorted by: Best Match Show Resources per page
Advancements in Pharmacotherapy for Noncancerous Manifestations of HPV.

Journal of clinical medicine

Kollipara R, Ekhlassi E, Downing C, Guidry J, Lee M, Tyring SK.
PMID: 26239450
J Clin Med. 2015 Apr 24;4(5):832-46. doi: 10.3390/jcm4050832.

Human papillomavirus (HPV) is the most common sexually transmitted disease. Via infection of the basal epithelial cells, HPV causes numerous malignancies and noncancerous cutaneous manifestations. Noncancerous cutaneous manifestations of HPV, including common, plantar, plane, and anogenital warts, are among...

Cite
Kollipara R, Ekhlassi E, Downing C, et al. Advancements in Pharmacotherapy for Noncancerous Manifestations of HPV. J Clin Med. 2015;4(5):832-46doi: 10.3390/jcm4050832.
Kollipara, R., Ekhlassi, E., Downing, C., Guidry, J., Lee, M., & Tyring, S. K. (2015). Advancements in Pharmacotherapy for Noncancerous Manifestations of HPV. Journal of clinical medicine, 4(5), 832-46. https://doi.org/10.3390/jcm4050832
Kollipara, Ramya, et al. "Advancements in Pharmacotherapy for Noncancerous Manifestations of HPV." Journal of clinical medicine vol. 4,5 (2015): 832-46. doi: https://doi.org/10.3390/jcm4050832
Kollipara R, Ekhlassi E, Downing C, Guidry J, Lee M, Tyring SK. Advancements in Pharmacotherapy for Noncancerous Manifestations of HPV. J Clin Med. 2015 Apr 24;4(5):832-46. doi: 10.3390/jcm4050832. PMID: 26239450; PMCID: PMC4470201.
Copy Download .nbib Format: NLM
The benefit of consolidation radiotherapy to initial disease bulk in patients with advanced Hodgkin's disease who achieved complete remission after standard chemotherapy.

Journal of blood medicine

Bayoumi Y, Al-Homaidi A, Zaidi S, Tailor I, Motiabi I, Alshehri N, Al-Ghazali A, Almudaibigh S.
PMID: 25848329
J Blood Med. 2015 Mar 20;6:87-92. doi: 10.2147/JBM.S69267. eCollection 2015.

BACKGROUND/PURPOSE: The aim of this study was to evaluate the role of consolidation radiotherapy (RT) in advanced-stage Hodgkin's disease (HD) with initial bulky sites after radiological complete remission (CR) or partial response (PR) with positron emission tomography-negative (metabolic CR)...

Cite
Bayoumi Y, Al-Homaidi A, Zaidi S, et al. The benefit of consolidation radiotherapy to initial disease bulk in patients with advanced Hodgkin's disease who achieved complete remission after standard chemotherapy. J Blood Med. 2015;6:87-92doi: 10.2147/JBM.S69267.
Bayoumi, Y., Al-Homaidi, A., Zaidi, S., Tailor, I., Motiabi, I., Alshehri, N., Al-Ghazali, A., & Almudaibigh, S. (2015). The benefit of consolidation radiotherapy to initial disease bulk in patients with advanced Hodgkin's disease who achieved complete remission after standard chemotherapy. Journal of blood medicine, 687-92. https://doi.org/10.2147/JBM.S69267
Bayoumi, Yasser, et al. "The benefit of consolidation radiotherapy to initial disease bulk in patients with advanced Hodgkin's disease who achieved complete remission after standard chemotherapy." Journal of blood medicine vol. 6 (2015): 87-92. doi: https://doi.org/10.2147/JBM.S69267
Bayoumi Y, Al-Homaidi A, Zaidi S, Tailor I, Motiabi I, Alshehri N, Al-Ghazali A, Almudaibigh S. The benefit of consolidation radiotherapy to initial disease bulk in patients with advanced Hodgkin's disease who achieved complete remission after standard chemotherapy. J Blood Med. 2015 Mar 20;6:87-92. doi: 10.2147/JBM.S69267. eCollection 2015. PMID: 25848329; PMCID: PMC4374789.
Copy Download .nbib Format: NLM
TIAM1 inhibits lung fibroblast differentiation in pulmonary fibrosis.

Experimental and therapeutic medicine

Huang Z, Sun S, Yang C, Zheng J, Nan Y, Zhao R, Lang Z, Li H, Ma L.
PMID: 29067109
Exp Ther Med. 2017 Nov;14(5):4254-4262. doi: 10.3892/etm.2017.5024. Epub 2017 Aug 24.

The differentiation of fibroblasts to myofibroblasts is critical for the development of idiopathic pulmonary fibrosis (IPF). T-cell lymphoma invasion and metastasis 1 (TIAM1) is known to be associated with amyotrophic lateral sclerosis 1 and colorectal cancer; however, its role...

Cite
Huang Z, Sun S, Yang C, et al. TIAM1 inhibits lung fibroblast differentiation in pulmonary fibrosis. Exp Ther Med. 2017;14(5):4254-4262doi: 10.3892/etm.2017.5024.
Huang, Z., Sun, S., Yang, C., Zheng, J., Nan, Y., Zhao, R., Lang, Z., Li, H., & Ma, L. (2017). TIAM1 inhibits lung fibroblast differentiation in pulmonary fibrosis. Experimental and therapeutic medicine, 14(5), 4254-4262. https://doi.org/10.3892/etm.2017.5024
Huang, Zhicheng, et al. "TIAM1 inhibits lung fibroblast differentiation in pulmonary fibrosis." Experimental and therapeutic medicine vol. 14,5 (2017): 4254-4262. doi: https://doi.org/10.3892/etm.2017.5024
Huang Z, Sun S, Yang C, Zheng J, Nan Y, Zhao R, Lang Z, Li H, Ma L. TIAM1 inhibits lung fibroblast differentiation in pulmonary fibrosis. Exp Ther Med. 2017 Nov;14(5):4254-4262. doi: 10.3892/etm.2017.5024. Epub 2017 Aug 24. PMID: 29067109; PMCID: PMC5647702.
Copy Download .nbib Format: NLM
Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis.

ACS medicinal chemistry letters

Huang Z, Li H, Zhang Q, Lu F, Hong M, Zhang Z, Guo X, Zhu Y, Li S, Liu H.
PMID: 29152045
ACS Med Chem Lett. 2017 Sep 30;8(11):1142-1147. doi: 10.1021/acsmedchemlett.7b00164. eCollection 2017 Nov 09.

Idiopathic pulmonary fibrosis (IPF) is a serious and deadly disease for which treatment options are limited. The recent approval of antifibrosis agent nintedanib represents one of the first therapeutic approaches for the treatment of IPF. Here, we report novel...

Cite
Huang Z, Li H, Zhang Q, et al. Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis. ACS Med Chem Lett. 2017;8(11):1142-1147doi: 10.1021/acsmedchemlett.7b00164.
Huang, Z., Li, H., Zhang, Q., Lu, F., Hong, M., Zhang, Z., Guo, X., Zhu, Y., Li, S., & Liu, H. (2017). Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis. ACS medicinal chemistry letters, 8(11), 1142-1147. https://doi.org/10.1021/acsmedchemlett.7b00164
Huang, Zhenhua, et al. "Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis." ACS medicinal chemistry letters vol. 8,11 (2017): 1142-1147. doi: https://doi.org/10.1021/acsmedchemlett.7b00164
Huang Z, Li H, Zhang Q, Lu F, Hong M, Zhang Z, Guo X, Zhu Y, Li S, Liu H. Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis. ACS Med Chem Lett. 2017 Sep 30;8(11):1142-1147. doi: 10.1021/acsmedchemlett.7b00164. eCollection 2017 Nov 09. PMID: 29152045; PMCID: PMC5682619.
Copy Download .nbib Format: NLM
Adipose tissue-derived stem cells ameliorates dermal fibrosis in a mouse model of scleroderma.

Asian Pacific journal of tropical medicine

Chen W, Xia ZK, Zhang MH, Ding GC, Zhang XY, Wang ZX, Yang RY.
PMID: 28107865
Asian Pac J Trop Med. 2017 Jan;10(1):52-56. doi: 10.1016/j.apjtm.2016.10.005. Epub 2016 Nov 09.

OBJECTIVE: To investigate the therapeutic potential of adipose-derived stem cells (ADSCs) for limited cutaneous scleroderma (LS) in mouse models.METHODS: ADSCs were isolated from pathogen-free female C57BL/6 mice and LS was induced in wild type (WT) C57BL/6 mice via daily...

Cite
Chen W, Xia ZK, Zhang MH, et al. Adipose tissue-derived stem cells ameliorates dermal fibrosis in a mouse model of scleroderma. Asian Pac J Trop Med. 2016;10(1):52-56doi: 10.1016/j.apjtm.2016.10.005.
Chen, W., Xia, Z. K., Zhang, M. H., Ding, G. C., Zhang, X. Y., Wang, Z. X., & Yang, R. Y. (2017). Adipose tissue-derived stem cells ameliorates dermal fibrosis in a mouse model of scleroderma. Asian Pacific journal of tropical medicine, 10(1), 52-56. https://doi.org/10.1016/j.apjtm.2016.10.005
Chen, Wei, et al. "Adipose tissue-derived stem cells ameliorates dermal fibrosis in a mouse model of scleroderma." Asian Pacific journal of tropical medicine vol. 10,1 (2017): 52-56. doi: https://doi.org/10.1016/j.apjtm.2016.10.005
Chen W, Xia ZK, Zhang MH, Ding GC, Zhang XY, Wang ZX, Yang RY. Adipose tissue-derived stem cells ameliorates dermal fibrosis in a mouse model of scleroderma. Asian Pac J Trop Med. 2017 Jan;10(1):52-56. doi: 10.1016/j.apjtm.2016.10.005. Epub 2016 Nov 09. PMID: 28107865.
Copy Download .nbib Format: NLM
Differences in outcome of patients with syncytial variant Hodgkin lymphoma compared with typical nodular sclerosis Hodgkin lymphoma.

Therapeutic advances in hematology

Sethi T, Nguyen V, Li S, Morgan D, Greer J, Reddy N.
PMID: 28042455
Ther Adv Hematol. 2017 Jan;8(1):13-20. doi: 10.1177/2040620716676256. Epub 2016 Oct 30.

BACKGROUND: Nodular sclerosis Hodgkin lymphoma (NS-HL) is the most common subtype of HL and usually has a good prognosis. A variant of NS, the syncytial variant (SV) has well-established histopathologic features but little is known about its clinical behavior....

Cite
Sethi T, Nguyen V, Li S, et al. Differences in outcome of patients with syncytial variant Hodgkin lymphoma compared with typical nodular sclerosis Hodgkin lymphoma. Ther Adv Hematol. 2016;8(1):13-20doi: 10.1177/2040620716676256.
Sethi, T., Nguyen, V., Li, S., Morgan, D., Greer, J., & Reddy, N. (2017). Differences in outcome of patients with syncytial variant Hodgkin lymphoma compared with typical nodular sclerosis Hodgkin lymphoma. Therapeutic advances in hematology, 8(1), 13-20. https://doi.org/10.1177/2040620716676256
Sethi, Tarsheen, et al. "Differences in outcome of patients with syncytial variant Hodgkin lymphoma compared with typical nodular sclerosis Hodgkin lymphoma." Therapeutic advances in hematology vol. 8,1 (2017): 13-20. doi: https://doi.org/10.1177/2040620716676256
Sethi T, Nguyen V, Li S, Morgan D, Greer J, Reddy N. Differences in outcome of patients with syncytial variant Hodgkin lymphoma compared with typical nodular sclerosis Hodgkin lymphoma. Ther Adv Hematol. 2017 Jan;8(1):13-20. doi: 10.1177/2040620716676256. Epub 2016 Oct 30. PMID: 28042455; PMCID: PMC5167078.
Copy Download .nbib Format: NLM
Histolgical and immunohistochemical study on the effect of stem cell therapy on bleomycin induced pulmonary fibrosis in albino rat.

International journal of stem cells

Sabry MM, Elkalawy SA, Abo-Elnour RK, Abd-El-Maksod DF.
PMID: 24921026
Int J Stem Cells. 2014 May;7(1):33-42. doi: 10.15283/ijsc.2014.7.1.33.

AIM OF WORK: To demonstrate the bleomycin induced histological changes in the lung and the possible protective and/or therapeutic effect of stem cell therapy.MATERIALS AND METHODS: Study was carried out on 36 adult male albino rats, classified into 4...

Cite
Sabry MM, Elkalawy SA, Abo-Elnour RK, et al. Histolgical and immunohistochemical study on the effect of stem cell therapy on bleomycin induced pulmonary fibrosis in albino rat. Int J Stem Cells. 2014;7(1):33-42doi: 10.15283/ijsc.2014.7.1.33.
Sabry, M. M., Elkalawy, S. A., Abo-Elnour, R. K., & Abd-El-Maksod, D. F. (2014). Histolgical and immunohistochemical study on the effect of stem cell therapy on bleomycin induced pulmonary fibrosis in albino rat. International journal of stem cells, 7(1), 33-42. https://doi.org/10.15283/ijsc.2014.7.1.33
Sabry, Marwa Mohammed, et al. "Histolgical and immunohistochemical study on the effect of stem cell therapy on bleomycin induced pulmonary fibrosis in albino rat." International journal of stem cells vol. 7,1 (2014): 33-42. doi: https://doi.org/10.15283/ijsc.2014.7.1.33
Sabry MM, Elkalawy SA, Abo-Elnour RK, Abd-El-Maksod DF. Histolgical and immunohistochemical study on the effect of stem cell therapy on bleomycin induced pulmonary fibrosis in albino rat. Int J Stem Cells. 2014 May;7(1):33-42. doi: 10.15283/ijsc.2014.7.1.33. PMID: 24921026; PMCID: PMC4049730.
Copy Download .nbib Format: NLM
CEPP regimen (cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function.

Biomarker research

Thakar K, Novero A, Das A, Lisinschi A, Mehta B, Ahmed T, Liu D.
PMID: 24991411
Biomark Res. 2014 Jun 23;2:12. doi: 10.1186/2050-7771-2-12. eCollection 2014.

ABVD regimen (doxorubicin, bleomycin, vinblastine and dacarbazine) remains the most commonly used front-line therapy for Hodgkin lymphoma. However, atypical and extranodal presentations present challenges to initial therapy, especially in the presence of renal and liver failure. We hereby present...

Cite
Thakar K, Novero A, Das A, et al. CEPP regimen (cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function. Biomark Res. 2014;2:12doi: 10.1186/2050-7771-2-12.
Thakar, K., Novero, A., Das, A., Lisinschi, A., Mehta, B., Ahmed, T., & Liu, D. (2014). CEPP regimen (cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function. Biomarker research, 212. https://doi.org/10.1186/2050-7771-2-12
Thakar, Keyur, et al. "CEPP regimen (cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function." Biomarker research vol. 2 (2014): 12. doi: https://doi.org/10.1186/2050-7771-2-12
Thakar K, Novero A, Das A, Lisinschi A, Mehta B, Ahmed T, Liu D. CEPP regimen (cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function. Biomark Res. 2014 Jun 23;2:12. doi: 10.1186/2050-7771-2-12. eCollection 2014. PMID: 24991411; PMCID: PMC4078319.
Copy Download .nbib Format: NLM
Fibrocytes in the fibrotic lung: altered phenotype detected by flow cytometry.

Frontiers in pharmacology

Reese C, Lee R, Bonner M, Perry B, Heywood J, Silver RM, Tourkina E, Visconti RP, Hoffman S.
PMID: 24999331
Front Pharmacol. 2014 Jun 16;5:141. doi: 10.3389/fphar.2014.00141. eCollection 2014.

Fibrocytes are bone marrow hematopoietic-derived cells that also express a mesenchymal cell marker (commonly collagen I) and participate in fibrotic diseases of multiple organs. Given their origin, they or their precursors must be circulating cells before recruitment into target...

Cite
Reese C, Lee R, Bonner M, et al. Fibrocytes in the fibrotic lung: altered phenotype detected by flow cytometry. Front Pharmacol. 2014;5:141doi: 10.3389/fphar.2014.00141.
Reese, C., Lee, R., Bonner, M., Perry, B., Heywood, J., Silver, R. M., Tourkina, E., Visconti, R. P., & Hoffman, S. (2014). Fibrocytes in the fibrotic lung: altered phenotype detected by flow cytometry. Frontiers in pharmacology, 5141. https://doi.org/10.3389/fphar.2014.00141
Reese, Charles, et al. "Fibrocytes in the fibrotic lung: altered phenotype detected by flow cytometry." Frontiers in pharmacology vol. 5 (2014): 141. doi: https://doi.org/10.3389/fphar.2014.00141
Reese C, Lee R, Bonner M, Perry B, Heywood J, Silver RM, Tourkina E, Visconti RP, Hoffman S. Fibrocytes in the fibrotic lung: altered phenotype detected by flow cytometry. Front Pharmacol. 2014 Jun 16;5:141. doi: 10.3389/fphar.2014.00141. eCollection 2014. PMID: 24999331; PMCID: PMC4058709.
Copy Download .nbib Format: NLM
No effect of pirfenidone treatment in fulminant bleomycin-induced pneumonitis.

Respiratory medicine case reports

Bendstrup E, Hyldgaard C, Agerbæk M, Andersen CU, Hilberg O.
PMID: 26029540
Respir Med Case Rep. 2014 May 02;12:47-9. doi: 10.1016/j.rmcr.2013.12.010. eCollection 2014.

Bleomycin-induced pneumonitis (BIP) is a serious and potentially fatal adverse effect of bleomycin. Currently, BIP is treated on an empirical basis with high dose steroid. Pirfenidone is a new antifibrotic drug, which has been proven beneficial in idiopathic pulmonary...

Cite
Bendstrup E, Hyldgaard C, Agerbæk M, et al. No effect of pirfenidone treatment in fulminant bleomycin-induced pneumonitis. Respir Med Case Rep. 2014;12:47-9doi: 10.1016/j.rmcr.2013.12.010.
Bendstrup, E., Hyldgaard, C., Agerbæk, M., Andersen, C. U., & Hilberg, O. (2014). No effect of pirfenidone treatment in fulminant bleomycin-induced pneumonitis. Respiratory medicine case reports, 1247-9. https://doi.org/10.1016/j.rmcr.2013.12.010
Bendstrup, Elisabeth, et al. "No effect of pirfenidone treatment in fulminant bleomycin-induced pneumonitis." Respiratory medicine case reports vol. 12 (2014): 47-9. doi: https://doi.org/10.1016/j.rmcr.2013.12.010
Bendstrup E, Hyldgaard C, Agerbæk M, Andersen CU, Hilberg O. No effect of pirfenidone treatment in fulminant bleomycin-induced pneumonitis. Respir Med Case Rep. 2014 May 02;12:47-9. doi: 10.1016/j.rmcr.2013.12.010. eCollection 2014. PMID: 26029540; PMCID: PMC4061441.
Copy Download .nbib Format: NLM
A Literature Review and Case Report of Metastatic Pure Choriocarcinoma.

Case reports in oncological medicine

Lin D, Tan AJ, Singh-Rai R.
PMID: 26649213
Case Rep Oncol Med. 2015;2015:345018. doi: 10.1155/2015/345018. Epub 2015 Nov 16.

In 2012, testicular cancer was estimated to account for 940 disability adjusted life years in Australia; of these, 450 were years lost due to premature death and 500 were years of healthy life lost due to disease, disability, or...

Cite
Lin D, Tan AJ, Singh-Rai R. A Literature Review and Case Report of Metastatic Pure Choriocarcinoma. Case Rep Oncol Med. 2015;2015:345018doi: 10.1155/2015/345018.
Lin, D., Tan, A. J., & Singh-Rai, R. (2015). A Literature Review and Case Report of Metastatic Pure Choriocarcinoma. Case reports in oncological medicine, 2015345018. https://doi.org/10.1155/2015/345018
Lin, Diwei, et al. "A Literature Review and Case Report of Metastatic Pure Choriocarcinoma." Case reports in oncological medicine vol. 2015 (2015): 345018. doi: https://doi.org/10.1155/2015/345018
Lin D, Tan AJ, Singh-Rai R. A Literature Review and Case Report of Metastatic Pure Choriocarcinoma. Case Rep Oncol Med. 2015;2015:345018. doi: 10.1155/2015/345018. Epub 2015 Nov 16. PMID: 26649213; PMCID: PMC4663315.
Copy Download .nbib Format: NLM
Caveolin-1 regulates chemokine receptor 5-mediated contribution of bone marrow-derived cells to dermal fibrosis.

Frontiers in pharmacology

Lee R, Perry B, Heywood J, Reese C, Bonner M, Hatfield CM, Silver RM, Visconti RP, Hoffman S, Tourkina E.
PMID: 24966836
Front Pharmacol. 2014 Jun 11;5:140. doi: 10.3389/fphar.2014.00140. eCollection 2014.

In fibrotic diseases caveolin-1 underexpression in fibroblasts results in collagen overexpression and in monocytes leads to hypermigration. These profibrotic behaviors are blocked by the caveolin-1 scaffolding domain peptide (CSD) which compensates for caveolin-1 deficiency. Monocytes and fibroblasts are related...

Cite
Lee R, Perry B, Heywood J, et al. Caveolin-1 regulates chemokine receptor 5-mediated contribution of bone marrow-derived cells to dermal fibrosis. Front Pharmacol. 2014;5:140doi: 10.3389/fphar.2014.00140.
Lee, R., Perry, B., Heywood, J., Reese, C., Bonner, M., Hatfield, C. M., Silver, R. M., Visconti, R. P., Hoffman, S., & Tourkina, E. (2014). Caveolin-1 regulates chemokine receptor 5-mediated contribution of bone marrow-derived cells to dermal fibrosis. Frontiers in pharmacology, 5140. https://doi.org/10.3389/fphar.2014.00140
Lee, Rebecca, et al. "Caveolin-1 regulates chemokine receptor 5-mediated contribution of bone marrow-derived cells to dermal fibrosis." Frontiers in pharmacology vol. 5 (2014): 140. doi: https://doi.org/10.3389/fphar.2014.00140
Lee R, Perry B, Heywood J, Reese C, Bonner M, Hatfield CM, Silver RM, Visconti RP, Hoffman S, Tourkina E. Caveolin-1 regulates chemokine receptor 5-mediated contribution of bone marrow-derived cells to dermal fibrosis. Front Pharmacol. 2014 Jun 11;5:140. doi: 10.3389/fphar.2014.00140. eCollection 2014. PMID: 24966836; PMCID: PMC4052341.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 1347 entries